Is Platinib effective in treating medullary thyroid cancer?

Platinib, as a potent and highly selective RET kinase inhibitor, has attracted widespread attention in the field of thyroid cancer treatment in recent years. Especially in the treatment of RETmutant medullary thyroid cancer (MTC), platinib has shown impressive clinical effects.

According to data from multiple clinical studies, platinib has shown high efficacy in the treatment of RET mutant medullary thyroid cancer. For example, in updated data from the ARROW study, for treatment-naïve RET late-mutation For patients with MTC, the objective response rate (ORR) of first-line treatment with platinib is as high as 77%. This data strongly supports the superior performance of platinib in treating this patient population. At the same time, for previously treated patients with RETmutated MTC, platinib also showed good efficacy, with ORR reaching 56%.

In addition to highORR, platinib also showed durability of efficacy. In the ARROW study, the median duration of response (DoR), median progression-free survival (PFS) and median overall survival (OS) have not yet been reached, but the DoR rate at 18 months is as high as 80%, which shows that Platinib can not only take effect quickly, but also the efficacy can be maintained for a long time. For previously treated patients, the median PFS and median DoR reached 26 months, further proving the durability of platinib's efficacy.

Platinib can also significantly prolong patient survival. Study shows that patients with RET mutation-positive medullary thyroid cancer who received platinib at 18 months< span>OSThe rate can reach 90.8%. This data is significantly higher than other traditional treatment methods, showing the unique advantages of platinib in improving patient survival.

In terms of safety, Platinib also showed good characteristics. Multiple clinical studies have shown that the side effects of platinib are mainly mild to moderate and can be tolerated by most patients. This provides assurance that patients will continue to receive treatment, thereby helping to achieve longer survival and improved quality of life.

Compared with traditional chemotherapy and radiotherapy methods, platinib has higher specificity and lower toxic side effects. Traditional chemotherapy and radiotherapy often cause greater damage to normal cells, but Platinib, as a targeted therapy drug, can act on cancer cells more accurately and reduce damage to normal cells.

Many experts expressed their opinions at academic conferences and journals and spoke highly of the efficacy of platinib in the treatment ofRETmutated medullary thyroid cancer. They believe that platinib provides a new and effective treatment option for such patients. At the same time, clinical practice has also proven that platinib can significantly improve patients' quality of life and survival.

Platinib has shown significant clinical efficacy in the treatment ofRETmutated medullary thyroid carcinoma. Its highORR, durability of efficacy, improved survival, and good safety and tolerability make platinib an ideal treatment option for these patients. In the future, with the accumulation of more clinical data and in-depth research, we have reason to believe that platinib will play a greater role in the treatment of thyroid cancer.